BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22438555)

  • 1. Functional characterization of residues required for the herpes simplex virus 1 E3 ubiquitin ligase ICP0 to interact with the cellular E2 ubiquitin-conjugating enzyme UBE2D1 (UbcH5a).
    Vanni E; Gatherer D; Tong L; Everett RD; Boutell C
    J Virol; 2012 Jun; 86(11):6323-33. PubMed ID: 22438555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro.
    Boutell C; Sadis S; Everett RD
    J Virol; 2002 Jan; 76(2):841-50. PubMed ID: 11752173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequences related to SUMO interaction motifs in herpes simplex virus 1 protein ICP0 act cooperatively to stimulate virus infection.
    Everett RD; Boutell C; Pheasant K; Cuchet-Lourenço D; Orr A
    J Virol; 2014 Mar; 88(5):2763-74. PubMed ID: 24352468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Tale of Two PMLs: Elements Regulating a Differential Substrate Recognition by the ICP0 E3 Ubiquitin Ligase of Herpes Simplex Virus 1.
    Zheng Y; Samrat SK; Gu H
    J Virol; 2016 Dec; 90(23):10875-10885. PubMed ID: 27681131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A RING finger ubiquitin ligase is protected from autocatalyzed ubiquitination and degradation by binding to ubiquitin-specific protease USP7.
    Canning M; Boutell C; Parkinson J; Everett RD
    J Biol Chem; 2004 Sep; 279(37):38160-8. PubMed ID: 15247261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herpes simplex virus 1-infected cell protein 0 contains two E3 ubiquitin ligase sites specific for different E2 ubiquitin-conjugating enzymes.
    Hagglund R; Van Sant C; Lopez P; Roizman B
    Proc Natl Acad Sci U S A; 2002 Jan; 99(2):631-6. PubMed ID: 11805320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatory protein ICP0.
    Boutell C; Orr A; Everett RD
    J Virol; 2003 Aug; 77(16):8686-94. PubMed ID: 12885887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes simplex virus 1 mutant in which the ICP0 HUL-1 E3 ubiquitin ligase site is disrupted stabilizes cdc34 but degrades D-type cyclins and exhibits diminished neurotoxicity.
    Hagglund R; Roizman B
    J Virol; 2003 Dec; 77(24):13194-202. PubMed ID: 14645576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner.
    Boutell C; Everett R; Hilliard J; Schaffer P; Orr A; Davido D
    J Virol; 2008 Nov; 82(21):10647-56. PubMed ID: 18715910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence.
    Boutell C; Cuchet-Lourenço D; Vanni E; Orr A; Glass M; McFarlane S; Everett RD
    PLoS Pathog; 2011 Sep; 7(9):e1002245. PubMed ID: 21949651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The degradation of promyelocytic leukemia and Sp100 proteins by herpes simplex virus 1 is mediated by the ubiquitin-conjugating enzyme UbcH5a.
    Gu H; Roizman B
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8963-8. PubMed ID: 12855769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The viral ubiquitin ligase ICP0 is neither sufficient nor necessary for degradation of the cellular DNA sensor IFI16 during herpes simplex virus 1 infection.
    Cuchet-Lourenço D; Anderson G; Sloan E; Orr A; Everett RD
    J Virol; 2013 Dec; 87(24):13422-32. PubMed ID: 24089555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The herpes simplex virus type 1 (HSV-1) regulatory protein ICP0 interacts with and Ubiquitinates p53.
    Boutell C; Everett RD
    J Biol Chem; 2003 Sep; 278(38):36596-602. PubMed ID: 12855695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two overlapping regions within the N-terminal half of the herpes simplex virus 1 E3 ubiquitin ligase ICP0 facilitate the degradation and dissociation of PML and dissociation of Sp100 from ND10.
    Perusina Lanfranca M; Mostafa HH; Davido DJ
    J Virol; 2013 Dec; 87(24):13287-96. PubMed ID: 24089549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpes simplex virus 1 ubiquitin ligase ICP0 interacts with PML isoform I and induces its SUMO-independent degradation.
    Cuchet-Lourenço D; Vanni E; Glass M; Orr A; Everett RD
    J Virol; 2012 Oct; 86(20):11209-22. PubMed ID: 22875967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of SUMO-SIM Interaction on the ICP0-Mediated Degradation of PML Isoform II and Its Associated Proteins in Herpes Simplex Virus 1 Infection.
    Jan Fada B; Kaadi E; Samrat SK; Zheng Y; Gu H
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32295906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Small-Molecule Inhibitors Targeting the E3 Ubiquitin Ligase Activity of the Herpes Simplex Virus 1 ICP0 Protein Using an
    Deschamps T; Waisner H; Dogrammatzis C; Roy A; Chacko S; Perera C; Prisinzano TE; Kalamvoki M
    J Virol; 2019 Jul; 93(13):. PubMed ID: 30996104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of TRIM27 as a novel degradation target of herpes simplex virus 1 ICP0.
    Conwell SE; White AE; Harper JW; Knipe DM
    J Virol; 2015 Jan; 89(1):220-9. PubMed ID: 25320289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The infected cell protein 0 of herpes simplex virus 1 dynamically interacts with proteasomes, binds and activates the cdc34 E2 ubiquitin-conjugating enzyme, and possesses in vitro E3 ubiquitin ligase activity.
    Van Sant C; Hagglund R; Lopez P; Roizman B
    Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8815-20. PubMed ID: 11447293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal phosphorylation sites of herpes simplex virus 1 ICP0 differentially regulate its activities and enhance viral replication.
    Mostafa HH; Thompson TW; Davido DJ
    J Virol; 2013 Feb; 87(4):2109-19. PubMed ID: 23221554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.